- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-12-03
DOI
10.3389/fimmu.2019.02847
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bedeutung des follikulären Penetrationswegs für den Wirkstofftransport mittels Nanocarriern
- (2019) J. Lademann et al. HAUTARZT
- Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
- (2019) Masayoshi Harigai et al. Modern Rheumatology
- JAK inhibitors and alopecia areata
- (2019) Amos Gilhar et al. LANCET
- JAK inhibitors for alopecia areata: a systematic review and meta-analysis
- (2019) Kevin Phan et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature
- (2019) Nicole Relke et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib – A report of two cases
- (2019) Sarah Wendel et al. JOURNAL OF AUTOIMMUNITY
- PF-06651600, a dual JAK3/TEC family kinase inhibitor
- (2019) Hua Xu et al. ACS Chemical Biology
- Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
- (2019) Christopher Ma et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update
- (2019) Satoshi Kubo et al. Expert Review of Clinical Immunology
- Successful treatment of cheilitis granulomatosa with lenalidomide
- (2019) F. Solimani et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis
- (2019) Giovanni Almanzar et al. RHEUMATOLOGY
- Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib
- (2019) Diana S. Novikova et al. RHEUMATOLOGY INTERNATIONAL
- T cell pathology in skin inflammation
- (2019) Robert Sabat et al. Seminars in Immunopathology
- Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
- (2019) William Damsky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) inhibitors
- (2019) Jun Dai et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease
- (2019) Zhiwei Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pemphigus: Current and Future Therapeutic Strategies
- (2019) Dario Didona et al. Frontiers in Immunology
- Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus
- (2019) Farzan Solimani et al. Frontiers in Immunology
- Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomised, double‐blind, vehicle‐controlled Phase 2a study
- (2019) M. Worm et al. BRITISH JOURNAL OF DERMATOLOGY
- IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus
- (2019) Shuai Shao et al. Science Translational Medicine
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- (2019) Kata P. Szilveszter et al. Frontiers in Immunology
- Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
- (2019) Mueller et al. Journal of Clinical Medicine
- Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
- (2019) Alessia Alunno et al. Cells
- Open‐label pilot study of tofacitinib 2% for the treatment of refractory vitiligo
- (2019) P. Mobasher et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
- (2018) F. Valenzuela et al. BRITISH JOURNAL OF DERMATOLOGY
- Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor
- (2018) S. Nasifoglu et al. BRITISH JOURNAL OF DERMATOLOGY
- Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers
- (2018) Kent J. Weinhold et al. CLINICAL IMMUNOLOGY
- Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
- (2018) Ian C. Scott et al. DRUG SAFETY
- Aberrant cell signalling in PBMCs upon IFN-α stimulation in primary Sjögren's syndrome patients associates with type I interferon signature
- (2018) Richard Davies et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis
- (2018) Jürgen Brück et al. EXPERIMENTAL DERMATOLOGY
- Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention
- (2018) Jean-Frédéric Colombel INFLAMMATORY BOWEL DISEASES
- T H 1/T H 17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus
- (2018) Thomas Schmidt et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study
- (2018) Kenji Kabashima et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
- (2018) Andreas Wollenberg et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
- (2018) Gina A. Montealegre Sanchez et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
- (2018) Hidemi Nakagawa et al. JOURNAL OF DERMATOLOGY
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- (2018) A. Jabbari et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Genome-Wide MicroRNA Analysis Implicates miR-30b/d in the Etiology of Alopecia Areata
- (2018) Aylar Tafazzoli et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Development, Optimization, and Structure–Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold
- (2018) Michael Forster et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
- (2018) Michael L. Vazquez et al. JOURNAL OF MEDICINAL CHEMISTRY
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
- (2018) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Topical Janus kinase inhibitors: A review of applications in dermatology
- (2018) Anna-Marie Hosking et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The use of JAK inhibitors in the treatment of progressive systemic sclerosis
- (2018) S.C. Deverapalli et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Immune response patterns in non-communicable inflammatory skin diseases
- (2018) K. Eyerich et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Case report
- (2018) Qiao Yang et al. MEDICINE
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Translocation of a gut pathobiont drives autoimmunity in mice and humans
- (2018) S. Manfredo Vieira et al. SCIENCE
- Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
- (2018) Przemyslaw J. Kotyla Biomed Research International
- Gene Expression Profiling in Behcet’s Disease Indicates an Autoimmune Component in the Pathogenesis of the Disease and Opens New Avenues for Targeted Therapy
- (2018) Antonio Puccetti et al. Journal of Immunology Research
- Achieving Hidradenitis Suppurativa Response Score (HiSCR) Is Associated With Significant Improvement in Clinical and Patient-Reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II
- (2018) A Kimball et al. ACTA DERMATO-VENEREOLOGICA
- Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus
- (2018) Soheil Tavakolpour Dermatologic Therapy
- Tofacitinib for the treatment of lichen planopilaris: A case series
- (2018) Christine C. Yang et al. Dermatologic Therapy
- Targeted Therapies for Autoimmune Bullous Diseases: Current Status
- (2018) Kyle T. Amber et al. DRUGS
- Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations
- (2018) Henrik M. Hammarén et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Classification and management of adult inflammatory myopathies
- (2018) Albert Selva-O'Callaghan et al. LANCET NEUROLOGY
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib
- (2018) Stephanie Sarny et al. JAMA Ophthalmology
- JAK Inhibitors for Atopic Dermatitis: An Update
- (2018) Helen He et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
- (2018) Nikolas von Bubnoff et al. BMC CANCER
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
- (2018) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
- (2018) Nawaf Almutairi et al. DERMATOLOGY
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- (2018) S.C. Gordon et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
- (2018) William Damsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ansprechen einer Dermatomyositis mit Lungenbeteiligung auf eine Januskinase-Inhibitor-Therapie
- (2018) J. Hornig et al. ZEITSCHRIFT FUR RHEUMATOLOGIE
- Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate
- (2018) Jeffrey R Curtis et al. ARTHRITIS CARE & RESEARCH
- Hidradenitis Suppurativa
- (2017) Ditte Marie Lindhardt Saunte et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march
- (2017) Tali Czarnowicki et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis
- (2017) Robert Wolk et al. Journal of Clinical Lipidology
- Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease
- (2017) Stephan R Vavricka et al. Journal of Crohns & Colitis
- The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
- (2017) JianZhong Zhang et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Nickel Sulfate Promotes IL-17A Producing CD4+ T Cells by an IL-23-Dependent Mechanism Regulated by TLR4 and Jak-STAT Pathways
- (2017) Rami Bechara et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis
- (2017) Joseph F. Merola et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib for the treatment of alopecia areata and variants in adolescents
- (2017) Brittany G. Craiglow et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
- (2017) Cheryl B. Bayart et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
- (2017) Brooke Rothstein et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
- (2017) Roy Fleischmann et al. LANCET
- Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis
- (2017) K. Juczynska et al. MEDIATORS OF INFLAMMATION
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Managing side effects of JAK inhibitors for myelofibrosis in clinical practice
- (2017) Iram Saeed et al. Expert Review of Hematology
- Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis
- (2017) Debomita Chakraborty et al. Nature Communications
- A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis
- (2017) Yong Chen et al. Scientific Reports
- A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma
- (2017) Dirk Smith et al. PLoS Genetics
- The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature
- (2017) Tong Zhou et al. Scientific Reports
- Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
- (2016) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
- (2016) V.J. Ludbrook et al. BRITISH JOURNAL OF DERMATOLOGY
- Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum
- (2016) J.L. Blok et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Recent advances in dermatomyositis-specific autoantibodies
- (2016) Manabu Fujimoto et al. CURRENT OPINION IN RHEUMATOLOGY
- Antibiotic Treatment of Hidradenitis Suppurativa
- (2016) Vincenzo Bettoli et al. DERMATOLOGIC CLINICS
- A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus
- (2016) Madhvi Menon et al. IMMUNITY
- Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study
- (2016) James Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
- (2016) Thomas Werfel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis
- (2016) Robert Bissonnette et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- STAT3 Signaling in B Cells Is Critical for Germinal Center Maintenance and Contributes to the Pathogenesis of Murine Models of Lupus
- (2016) Chuanlin Ding et al. JOURNAL OF IMMUNOLOGY
- Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa
- (2016) Claire Hotz et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Atopic dermatitis
- (2016) Stephan Weidinger et al. LANCET
- Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus
- (2016) L Kahl et al. LUPUS
- New insights into the immunopathogenesis of systemic lupus erythematosus
- (2016) George C. Tsokos et al. Nature Reviews Rheumatology
- Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis
- (2016) Simon Tarp et al. RHEUMATOLOGY
- Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis
- (2016) Drew J. B. Kurtzman et al. JAMA Dermatology
- JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases
- (2016) Ana Karina Alves de Medeiros et al. PLoS One
- Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
- (2015) K L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
- (2015) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- The genetics of pyoderma gangrenosum and implications for treatment: a systematic review
- (2015) E.M. DeFilippis et al. BRITISH JOURNAL OF DERMATOLOGY
- A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
- (2015) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects
- (2015) C. Carniti et al. CLINICAL CANCER RESEARCH
- Ultraviolet light converts propranolol, a nonselective β-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand
- (2015) Karim Dorgham et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum
- (2015) Li Gao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling
- (2015) Wataru Amano et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The immunogenetics of Behçet's disease: A comprehensive review
- (2015) Masaki Takeuchi et al. JOURNAL OF AUTOIMMUNITY
- Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
- (2015) Alexandra Y. Kreins et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Simvastatin Prevents and Reverses Depigmentation in a Mouse Model of Vitiligo
- (2015) Priti Agarwal et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
- (2015) Lauren L. Levy et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis
- (2015) Wolf-Henning Boehncke et al. LANCET
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
- (2015) R Zeiser et al. LEUKEMIA
- The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders
- (2015) Rohit Saluja et al. MOLECULAR IMMUNOLOGY
- Clinical improvement in psoriasis with specific targeting of interleukin-23
- (2015) Tamara Kopp et al. NATURE
- Lupus erythematosus revisited
- (2015) Annegret Kuhn et al. Seminars in Immunopathology
- Cutaneous immunology: basics and new concepts
- (2015) Amir S. Yazdi et al. Seminars in Immunopathology
- Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
- (2015) Vibeke Strand et al. ARTHRITIS RESEARCH & THERAPY
- Development of Th17-associated interstitial kidney inflammation in lupus-prone mice lacking the gene encoding STAT-1
- (2015) Gloria Yiu et al. Arthritis & Rheumatology
- Immunology of Psoriasis
- (2014) Michelle A. Lowes et al. Annual Review of Immunology
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
- (2014) S. Spoerl et al. BLOOD
- Activation of the JAK/STAT pathway in Behcet’s disease
- (2014) A Tulunay et al. GENES AND IMMUNITY
- Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo
- (2014) Atsuo Tanimoto et al. INFLAMMATION RESEARCH
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts
- (2014) M. Onda et al. JOURNAL OF IMMUNOLOGY
- Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis
- (2014) Melissa G. Works et al. JOURNAL OF IMMUNOLOGY
- Systemic lupus erythematosus
- (2014) Larissa Lisnevskaia et al. LANCET
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
- (2014) Thorsten Hornung et al. NEW ENGLAND JOURNAL OF MEDICINE
- CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo
- (2014) M. Rashighi et al. Science Translational Medicine
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease
- (2013) M.-C. Bruggen et al. BLOOD
- A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
- (2013) W.C. Ports et al. BRITISH JOURNAL OF DERMATOLOGY
- Cutting Edge: STAT1 Is Required for IL-6-Mediated Bcl6 Induction for Early Follicular Helper Cell Differentiation
- (2013) Y. S. Choi et al. JOURNAL OF IMMUNOLOGY
- Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
- (2013) Naoko Okiyama et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Immunoexpression of Interleukin-22 and Interleukin-23 in Oral and Cutaneous Lichen Planus Lesions: A Preliminary Study
- (2013) Jun Chen et al. MEDIATORS OF INFLAMMATION
- Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus
- (2013) M-P Piccinni et al. ORAL DISEASES
- Effects of the Janus Kinase Inhibitor CP-690550 (Tofacitinib) in a Rat Model of Oxazolone-Induced Chronic Dermatitis
- (2013) Yasutomo Fujii et al. PHARMACOLOGY
- Drug Delivery with Topically Applied Nanoparticles: Science Fiction or Reality?
- (2013) J. Lademann et al. SKIN PHARMACOLOGY AND PHYSIOLOGY
- Diagnosis and Treatment of Lichen Sclerosus
- (2012) Susanna K. Fistarol et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- IFN R signaling mediates alloreactive T-cell trafficking and GVHD
- (2012) J. Choi et al. BLOOD
- Functional STAT3 deficiency compromises the generation of human T follicular helper cells
- (2012) C. S. Ma et al. BLOOD
- Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis
- (2012) M-C. Lu et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8+ T-Cell Accumulation in the Skin
- (2012) John E. Harris et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Graft-versus-host disease
- (2012) Sharon R. Hymes et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
- (2012) Naresh Punwani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Alopecia Areata
- (2012) Amos Gilhar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lichen Planus
- (2012) Laurence Le Cleach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease
- (2012) Shiao Hui (Melissa) Liew et al. OPHTHALMOLOGY
- Possible role of interleukin-17 in the pathogenesis of lichen planus
- (2011) O. Shaker et al. BRITISH JOURNAL OF DERMATOLOGY
- Involvement of Tyrosine Kinase-2 in Both the IL-12/Th1 and IL-23/Th17 Axes In Vivo
- (2011) M. Ishizaki et al. JOURNAL OF IMMUNOLOGY
- Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2
- (2011) L. D. Lu et al. JOURNAL OF IMMUNOLOGY
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- An Autoimmune Phenotype in Vulvar Lichen Sclerosus and Lichen Planus: A Th1 Response and High Levels of MicroRNA-155
- (2011) Annelinde Terlou et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Comorbidity profiles among patients with alopecia areata: The importance of onset age, a nationwide population-based study
- (2011) Szu-Ying Chu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
- (2010) S. M. MCHUGH et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Deficiency of IL-22 Contributes to a Chronic Inflammatory Disease: Pathogenetic Mechanisms in Acne Inversa
- (2010) K. Wolk et al. JOURNAL OF IMMUNOLOGY
- Genome-wide association study in alopecia areata implicates both innate and adaptive immunity
- (2010) Lynn Petukhova et al. NATURE
- Genetic susceptibility to systemic lupus erythematosus in the genomic era
- (2010) Yun Deng et al. Nature Reviews Rheumatology
- -Secretase Gene Mutations in Familial Acne Inversa
- (2010) B. Wang et al. SCIENCE
- Activation of the interferon-γ signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells
- (2009) Thomas Karonitsch et al. ARTHRITIS AND RHEUMATISM
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- History of atopy or autoimmunity increases risk of alopecia areata
- (2009) Nazila Barahmani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Selectivity and therapeutic inhibition of kinases: to be or not to be?
- (2009) Kamran Ghoreschi et al. NATURE IMMUNOLOGY
- Vitiligo
- (2009) Alain Taïeb et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search